GlassScriptPhysician profile
Maricela Hernandez
NPI 1972830651
$2,377.38
in general payments reported to CMS, 2019-2025
26 companies · $792 in 2025
The $792 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $652 · 2023: $546 · 2024: $388 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.61 | 2022-2025 | |
| Ucb, INC. | $433.50 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Argenx US, INC. | $145.58 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Idorsia Pharmaceuticals US INC | $133.02 | 2022-2023 | Quviviq |
| Genzyme Corporation | $125.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $120.80 | 2022-2023 | Austedo |
| Pfizer INC. | $113.43 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $108.73 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $107.19 | 2022-2025 | Nuplazid, Daybue |
| Sk Life Science, INC. | $80.80 | 2022-2023 | |
| Eisai INC. | $80.62 | 2022-2023 | |
| Amgen INC. | $36.83 | 2022 | |
| Neurocrine Biosciences, INC. | $36.71 | 2022 | |
| Livanova USA, INC. | $36.25 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $33.23 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.76 | 2023 | Emgality |
| Merz Pharmaceuticals, LLC | $27.88 | 2022 | |
| Neurelis, INC. | $24.01 | 2022 | |
| Grifols USA, LLC | $22.84 | 2022 | |
| Biogen, INC. | $22.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.03 | 2022 | |
| Lundbeck LLC | $21.95 | 2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $21.90 | 2024 | |
| Exact Sciences Corporation | $21.89 | 2024 | Cologuard Collection Kit |
| Aquestive Therapeutics, INC. | $16.92 | 2022 | |
| Impel Pharmaceuticals INC. | $14.82 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maricela Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.